We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

115 hedge funds and large institutions have $482M invested in Karyopharm Therapeutics in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 49 increasing their positions, 34 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 34

0.88% more ownership

Funds ownership: 4.77% → 5.65% (+0.88%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3% less funds holding

Funds holding: 119 → 115 (-4)

12% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 17

35% less capital invested

Capital invested by funds: $738M → $482M (-$256M)

38% less call options, than puts

Call options by funds: $553K | Put options by funds: $894K

Holders
115
Holders Change
-4
Holders Change %
-3.36%
% of All Funds
2.56%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
49
Reduced
34
Closed
17
Calls
$553K
Puts
$894K
Net Calls
-$341K
Net Calls Change
+$2.08M

Top Buyers

Rank Fund Capital Flow
1
EA
Emerald Advisers
Pennsylvania
+$8.57M
2
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
+$8.17M
3
CS
Candriam SCA
Luxembourg
+$7.95M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$7.77M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$7.17M

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$7.69M
2
Millennium Management
Millennium Management
New York
-$4.37M
3
SSA
Schonfeld Strategic Advisors
New York
-$3.32M
4
DAM
Doheny Asset Management
California
-$1.89M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$1.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
California State Teachers Retirement System (CalSTRS)
51
California State Teachers Retirement System (CalSTRS)
California
$711K +$19.9K +118 +2%
Prudential Financial
52
Prudential Financial
New Jersey
$689K +$579K +3,434 +234%
BC
53
Birchview Capital
Vermont
$656K +$225K +1,334 +40%
Los Angeles Capital Management
54
Los Angeles Capital Management
California
$645K +$323K +1,916 +72%
SCA
55
Secor Capital Advisors
New York
$627K +$753K +4,463 New
Susquehanna International Group
56
Susquehanna International Group
Pennsylvania
$622K +$746K +4,423 New
CS
57
Credit Suisse
Switzerland
$618K +$224K +1,329 +43%
AllianceBernstein
58
AllianceBernstein
Tennessee
$601K +$24.6K +146 +4%
Bank of America
59
Bank of America
North Carolina
$557K -$127K -754 -16%
Squarepoint
60
Squarepoint
New York
$495K +$8.1K +48 +1%
State of Wisconsin Investment Board
61
State of Wisconsin Investment Board
Wisconsin
$468K +$6.75K +40 +1%
DAM
62
Doheny Asset Management
California
$441K -$1.89M -11,228 -78%
Wells Fargo
63
Wells Fargo
California
$426K +$36.6K +217 +8%
New York State Common Retirement Fund
64
New York State Common Retirement Fund
New York
$417K -$106K -626 -17%
ARTA
65
A.R.T. Advisors
New York
$411K +$101K +596 +26%
LTFS
66
Ladenburg Thalmann Financial Services
Florida
$392K +$470K +2,786 New
Balyasny Asset Management
67
Balyasny Asset Management
Illinois
$389K +$42.7K +253 +10%
CSS
68
Cubist Systematic Strategies
Connecticut
$349K +$194K +1,152 +87%
DMK
69
David M. Knott
$337K +$45K +267 +13%
AIG
70
American International Group
New York
$299K -$2.7K -16 -0.7%
VEA
71
Virtus ETF Advisers
New York
$288K +$50.4K +299 +17%
Manulife (Manufacturers Life Insurance)
72
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$284K -$8.43K -50 -2%
PAM
73
Premier Asset Management
Illinois
$282K +$338K +2,002 New
Jacobs Levy Equity Management
74
Jacobs Levy Equity Management
New Jersey
$275K +$1.01K +6 +0.3%
KAM
75
Kazazian Asset Management
Florida
$249K +$101K +600 +51%
1 2
3
4 5

KPTI Hedge Fund Activity: Q4 2018 in Review

115 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2018, worth a combined $482M — down 35% from $738M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of KPTI and 15 opened new positions — a net loss of 2 holders — while 34 trimmed existing stakes and 49 added.

The largest buyer was Emerald Advisers, adding an estimated $8.57M. The largest seller was Vanguard Group, cutting an estimated $7.69M.

  • 115 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2018, down from 119 in Q3 2018.
  • Funds reported $482M of Karyopharm Therapeutics stock for Q4 2018, down 35% quarter-over-quarter.
  • 15 funds opened new Karyopharm Therapeutics positions in Q4 2018 and 17 closed out, a net change of -2 holders.
  • The largest Karyopharm Therapeutics buyer in Q4 2018 was Emerald Advisers, an estimated $8.57M added.
  • The largest Karyopharm Therapeutics seller in Q4 2018 was Vanguard Group, an estimated $7.69M sold.

Based on aggregated 13F filings for Q4 2018.